港股異動 | 中藥股走高 固生堂(2273.HK)升超12%領漲
格隆匯2月9日丨次新股固生堂漲超12%領銜上漲,中國中藥漲5%,華潤醫藥、同仁堂國藥漲超2%,白雲山等紛紛跟漲。政策頻繁出台加快中醫藥特色發展,診所備案制加速中醫服務觸角延伸,中醫服務正處於快速發展期。民生證券指出,中醫在健康管理方面具備獨特優勢,可滿足我國急需的慢病管理需求。民營中醫連鎖化大勢所趨,並帶動上游高質量發展,建議關注連鎖中醫連鎖服務固生堂。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.